Table 1.
Clinical characteristics of the study population on TMA
| Characteristic | No. of Patients | % |
|---|---|---|
| PSA Recurrence Status | ||
| PSA Recurrence | 43 | 21.5 |
| Post-Prostatectomy Residual Tumor | 48 | 24 |
| None | 60 | 30 |
| Unknown | 49 | 24.5 |
| Vital Status | ||
| Alive | 157 | 78.5 |
| Dead | 36 | 18 |
| Lost to Follow-Up | 7 | 3.5 |
| Extraprostatic Extension | ||
| Focal | 47 | 23.5 |
| Established | 20 | 10 |
| Multifocal | 23 | 11.5 |
| None | 109 | 54.5 |
| Unknown | 1 | 0.5 |
| pT Stage | ||
| pT1b | 1 | 0.5 |
| pT2 | 1 | 0.5 |
| pT2+ | 4 | 2 |
| pT2a | 23 | 11.5 |
| pT2b | 77 | 38.5 |
| pT3 | 1 | 0.5 |
| pT3a | 67 | 33.5 |
| pT3b | 26 | 13 |
| pN Stage | ||
| pN0 | 166 | 83 |
| pN1 | 2 | 1 |
| pNX | 32 | 16 |
| pM Stage | ||
| pM0 | 178 | 89 |
| pMX | 22 | 11 |